Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
IBD quality initiative slashes ED utilization
Key clinical point: A quality improvement initiative reduced utilization rates for patients with inflammatory bowel disease among patients with Crohn’s disease and ulcerative colitis.
Major finding: Emergency department utilization rates declined 22% after the quality initiative.
Study details: Analysis of 15-month outcomes of 20,382 patients at 26 participating practices.
Disclosures: Dr. Melmed disclosed financial relationships with AbbVie, Boehringer-Ingelheim, Celgene, Jannsen, GSK, Medtronic, Pfizer, Samsung Bioepis, Takeda and Techlab. IBD Qorus, a quality of care collaborative of the Crohn’s & Colitis Foundation, receives support from AbbVie, AMAG, Helmsley Charitable Trust, Janssen, Nephoroceuticals, Pfizer, Takeda, and UCB.
Melmed GT et al. Crohn’s & Colitis Congress 2020, Session 28.